

448443843319355903345548453585571914451454857

Human Angiostatin (homologies of successive quantum frequencies with topoisomerase 1 are underlined by identical typographic characters; above in brackets: mouse)

(1)

538425353040548803525354043355922323683872313632504554838434

(8) (5)

443503938334355884834445355535632054840542535204535194252361

(6) (0) *****

60843257345445548384348548393733434589543443833333220338534

(5)

503054880431333206335692153363648335473354445483843405813936

334253895835432342233235541331335433335438604052880322333305

(2)

(8)

5352922533686553354834104354838434145039373343238958344553

+++++***

~~~~~

\*\*\*\*\*

This leads one to predict a strong metabolic agonism between those two proteins, and as a consequence that an inhibition of the former would reflect on the latter, thus des-inhibiting angiogenesis. On the contrary, most of these homologies (9 out of 12, among which the most significant ones underlined by +, \* et ~) disappear in the case of the mouse sequences (8 on angiostatin's side<sup>(2)</sup>, 5 on topoisomerase 1 side, 4 on both sides together); from which follows that the results observed there cannot be extended to man.

This has particularly severe consequences when the other regulatory pathways of angiogenesis are themselves invalidated, the thrombomodulin way through a mutation of p53 and the platelet factor 4 way through a mutation of platelet-derived growth factor  $\beta$ ; which would necessitate at the very least a molecular oncogenic analysis before experimenting, so that we can only recommend an immediate cease of these experimentations under present circumstances.

In addition, coming after a similar observation concerning the ob gene product leptin<sup>(3)</sup>, this strengthens the necessity that the implications of homologies of successive frequencies associated to protein biosyntheses be taken into account before undertaking any study of this kind.

(1) J. Sternheimer, *Scaling waves*, seminars given at the European University of Research (Paris), 1994-1995; *Method for epigenetic regulation of protein synthesis by scale resonance*, patent n° FR 92 06765 (1992), U. S. patent application n° SN 08/347.353; *Application des homologies de suites de fréquences de la troponine C à la prédiction de son métabolisme*, preprint (1995); *Régulation épigénétique de la biosynthèse des protéines et prédiction de leur métabolisme à partir de leur séquence*, preprint (1995).

(2) M. S. O'Reilly et al., *Angiostatin: a circulating endothelial inhibitor that suppresses angiogenesis and tumor growth*, Cold Spring Harbor Symp. LIX, p. 471 (1994); *Cell* 79, p. 315 (1994).

(3) J. Sternheimer, *Sur les différences métaboliques de la leptine (produit du gène ob) chez la souris et chez l'homme*, preprint European University of Research (1995).